Evidence map›Paper›PMID 42836759›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

A murine model of amyloid enhanced tauopathy: progressive changes in tau pathology and behavior.

Dylan J Finneran, Taylor Desjarlais, Brianna M Jackman, David Morgan, Marcia N Gordon

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. A murine model of amyloid-enhanced tauopathy: Comparison of wild-type and P301L-tau.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dylan J FinneranDept of Translational Neuroscience, College of Human Medicine, Michigan State University, Grand Rapids, Michigan, USA.ORCID https://orcid.org/0000-0001-7593-9432
Taylor DesjarlaisDept of Translational Neuroscience, College of Human Medicine, Michigan State University, Grand Rapids, Michigan, USA.
Brianna M JackmanDept of Translational Neuroscience, College of Human Medicine, Michigan State University, Grand Rapids, Michigan, USA.
David MorganDept of Translational Neuroscience, College of Human Medicine, Michigan State University, Grand Rapids, Michigan, USA.ORCID https://orcid.org/0000-0003-1224-7476
Marcia N GordonDept of Translational Neuroscience, College of Human Medicine, Michigan State University, Grand Rapids, Michigan, USA.

Funding

Research Education ComponentP30AG072931 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Henry L Paulson · 2021 to 2026
$26.5M
Influence of systemic immune inflammation upon the tauopathy phenotype in mouse modelsR01AG051500 · NIA · UNIVERSITY OF SOUTH FLORIDA · PI MORGAN, DAVID · 2016 to 2020
$3.5M
Discovery of functionally selective Alzheimer's disease therapeuticsR01AG055072 · NIA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI SCHREIHOFER, DEREK A · 2017 to 2021
$3.2M
Geroscience approaches to mitigate tauopathy in aged mouse brainR01AG062217 · NIA · MICHIGAN STATE UNIVERSITY · PI GORDON, MARCIA N · 2018 to 2022
$3.0M
Alzheimer's Association AARF-22-969267NIA NIH HHS P30 AG072931NIA NIH HHS R01 AG051500NIA NIH HHS R01 AG055072NIA NIH HHS R01 AG062217NIH HHS P30 AG072931NIH HHS R01 AG051500NIH HHS R01 AG055072NIH HHS R01 AG062217Rotary International Coins for Alzheimer's Research Trust
6 · The paper itself

Abstract

backgroundOur prior work demonstrated systemic P301L-tau injections in mice with mature amyloid resulted in several-fold enhancement of tauopathy compared to non-transgenic (NTg) littermates.

methodsAPP+PS1 mice were injected intravenously with AAV.CAP-B10 expressing P301L tau (A/P+P301L). Mice were tested behaviorally and tissues collected for measurement of amyloid and tau pathology.

resultsA/P+P301L mice have greater spatial navigation memory impairments than control APP+PS1 mice, or AAV-tau injected NTg mice. Tau phosphorylation and deposition increased from 5 to 9 months after injection, culminating in numerous Gallyas-positive presumptive neurofibrillary tangles. DISCUSSION: In this model of amyloid-enhanced tauopathy, tau pathology acts synergistically with amyloidosis to exacerbate cognitive impairments compared to amyloid-only mice. The tauopathy is progressive, with more severe behavioral impairments and neurofibrillary deposits at longer survival times. The temporal staging of pathology in this model resembles that of Alzheimer's disease and may be useful for interrogating the linkage between amyloid and tau pathology.

Indexed as

BrainTauopathiestau ProteinsAlzheimer DiseaseAmyloid beta-Protein PrecursorAnimalsDisease Models, AnimalDisease ProgressionHumansMiceMice, TransgenicNeurofibrillary TanglesPhosphorylationPresenilin-1Amyloid beta-Protein PrecursorPresenilin-1tau ProteinsAlzheimer's diseaseamyloidmouse modeltautime course

Identifiers

PMID42836759
PMCPMC13641094

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.